Access BridgeGap Ventures has invested $3.3 million in Series A financing in Vedantra Pharmaceuticals, an emerging drug discovery company developing a vaccine delivery platform. The Cambridge-based startup is a spinout from MIT, where it conducted its nanoparticle research.